← All trials
NCT04470427
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 27, 2020
- Primary completion
- Oct 27, 2022
- Completion date
- Oct 27, 2022
- First posted
- Jul 14, 2020
- Last posted
- Oct 28, 2020
- Enrollment
- 30000
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Moderna TherapeuticsLead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- Department of Health and Human ServicesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.